Date:			7/25/2023			
Your Name:			Wenhao Zhang			
Manuscript Title:			Homologous recombination deficiency score decreased after neoadjuvant chemotherapy in ovarian cancer patient: a case report and review of the literature			
Ma	nuscript Number (if k	nown):	GPM-23-19			
content of your manuscript. "Rela affected by the content of the ma						
epi		nsion, yo		example, if your manuscript pertains to the acturers of antihypertensive medication, even if		
	tem #1 below, report and the for disclosure is the		•	ithout time limit. For all other items, the time		
			ll entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
			Time traine, since the linear planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials,	Beijing of Trad	one Kanghua Foundation for the Development litional Chinese and Western Medicine (KH-LZX-013)	A grant for Wenhao Zhang for studying ovarian cancer		
1	present manuscript (e.g., funding, provision	Beijing of Trad	one Kanghua Foundation for the Development litional Chinese and Western Medicine (KH-	A grant for Wenhao Zhang for studying ovarian		
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Beijing of Trad	one Kanghua Foundation for the Development litional Chinese and Western Medicine (KH-	A grant for Wenhao Zhang for studying ovarian cancer		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Beijing of Trad	one Kanghua Foundation for the Development litional Chinese and Western Medicine (KH-	A grant for Wenhao Zhang for studying ovarian cancer Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Beijing of Trad 2021-L	Kanghua Foundation for the Development litional Chinese and Western Medicine (KH- LZX-013)	A grant for Wenhao Zhang for studying ovarian cancer Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	Beijing of Trad 2021-L	Kanghua Foundation for the Development litional Chinese and Western Medicine (KH-LZX-013) Time frame: past 36 month	A grant for Wenhao Zhang for studying ovarian cancer Click the tab key to add additional rows.		

			cations/Comments (e.g., if payments were o you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	nse place an "X" next	t to th	e following statement to indicate your agreeme	nt:

Date:	7/25/2023
Your Name:	Xiaojuan Lin
Manuscript Title:	Homologous recombination deficiency score decreased after neoadjuvant chemotherapy in ovarian cancer patient: a case report and review of the literature
Manuscript Number (if known):	GPM-23-19

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	1 All support for the present manuscript (e.g., funding, provision of study materials,		Time frame: Since the initial planning None	Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			Click the tab key to add additional rows.
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

			ifications/Comments (e.g., if payments were e to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:		7/25/2023	7/25/2023			
Your Name:		Rutie Yin	Rutie Yin			
Manuscript Title:		_	Homologous recombination deficiency score decreased after neoadjuvant chemotherapy in ovarian cancer patient: a case report and review of the literature			
Mai	nuscript Number (if k	nown): GPM-23-19)			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt." The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned.		pt. "Related" means f the manuscript. Dis in doubt about whet s/activities/interests shion, you should declarationed in the manuscript.	rt for the work reported in this manuscript without time limit. For all other items, the time			
			th whom you have this ate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time	frame: Since the initial planning	of the work		
present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for						
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	of Science and Tech factors affecting the	Sichuan Provincial Department Inology: Study on the key e diagnosis and treatment of Distetrics and gynecology	A grant for Rutie Yin Click the tab key to add additional rows.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	The Key Project of S of Science and Tech factors affecting the major diseases in ol	nology: Study on the key e diagnosis and treatment of	A grant for Rutie Yin Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	The Key Project of S of Science and Tech factors affecting the major diseases in ol	nology: Study on the key e diagnosis and treatment of bstetrics and gynecology	A grant for Rutie Yin Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

Teertify that Thave answered every question and have not aftered the words

Date:	7/25/2023
Your Name:	Xin Liao
Manuscript Title:	Homologous recombination deficiency score decreased after neoadjuvant chemotherapy in ovarian cancer patient: a case report and review of the literature
Manuscript Number (if known):	GPM-23-19

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

			ifications/Comments (e.g., if payments were e to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: \[\text{			

Date:			7/25/2023		
Your Name:			Qingli Li		
Manuscript Title:			Homologous recombination deficiency score decreased after neoadjuvant chemotherapy in ovarian cancer patient: a case report and review of the literature		
Maı	nuscript Number (if k	nown):	GPM-23-19		
content of your manuscript. "Related affected by the content of the manus			ask you to disclose all relationships/activities/interests listed below that are related to the ted" means any relation with for-profit or not-for-profit third parties whose interests may be suscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so.		
epic	-	nsion, yo		example, if your manuscript pertains to the facturers of antihypertensive medication, even if	
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
			ll entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials,	Techno	one ology Department of Sichuan Province, Key rogram (22ZDYF2592)	A grant for Qingli Li for studying ovarian cancer.	
	medical writing, article processing			Click the tab key to add additional rows.	
	charges, etc.) No time limit for this item.				
			Time frame: past 36 month	ns	
2	Grants or contracts from any entity (if not indicated in item #1 above).	× N	one		
3					

			cations/Comments (e.g., if payments were co you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None □	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			